Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

The FDA is further elevating a pacemaker recall from Boston Scientific that it first broadcasted in December, over certain ...

Ryvu Therapeutics is shrinking its headcount by 30% as the Polish biotech focuses its funds on taking its lead blood cancer ...

Kiniksa’s actions leave it focused on a cardiovascular disease pipeline led by the IL-1 antagonist KPL-387. The program is ...

With Lava Therapeutics still smoldering from the decision to dump its lead blood cancer drug, the biotech is now laying off ...

For the last six weeks, the shadow of potential layoffs has hung over Repare Therapeutics’ employees. Monday, staff learned ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...

BioCity Biopharma’s selective endothelin receptor type A (ETA) antagonist has reduced excess proteins in the urine of ...

As Alcon Research seeks to block investee Aurion Biotech from listing on the New York Stock Exchange, another investor has ...

Researchers studying a deadly virus discovered a key protein behind its lethality and successfully used antibodies to ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...